Cancer Letters
Volume 238, Issue 2 , Pages 180-187 , 18 July 2006

Significance of vascular stabilization for tumor growth and metastasis

  • Suleyman Ergun

      Affiliations

    • Center of Experimental Medicine, Institute of Anatomy I, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany
    • Corresponding Author InformationCorresponding author. Tel: +49 40 42803 4333; fax: +49 40 42803 8416.
    • ,
  • Derya Tilki

      Affiliations

    • Center of Experimental Medicine, Institute of Anatomy I, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany
    • ,
  • Leticia Oliveira-Ferrer

      Affiliations

    • Center of Experimental Medicine, Institute of Anatomy I, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany
    • ,
  • Gunter Schuch

      Affiliations

    • Department of Hematology/Oncology and Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, D-20246 Hamburg, Germany
    • ,
  • Nerbil Kilic

      Affiliations

    • Department of Hematology/Oncology and Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, D-20246 Hamburg, Germany

Received 11 June 2005 ,Accepted 23 June 2005.

References 

  1. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005;15:102–111
  2. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62
  3. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62:5381–5385
  4. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 2003;13:159–167
  5. Luttun A, Carmeliet P. Angiogenesis and lymphangiogenesis: highlights of the past year. Curr. Opin. Hematol. 2004;11:262–271
  6. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol Cell Physiol. 2004;287:C572–C579
  7. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95:3106–3112
  8. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer. 2002;2:826–835
  9. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 2002;29:10–14
  10. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis?. Cell. 1996;87:1153–1155
  11. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003;9:713–725
  12. Kalluri R. Angiogenesis: basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer. 2003;3:422–433
  13. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2003;163:1801–1815
  14. Ergun S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis. 2001;4:193–206
  15. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001;7:987–989
  16. Kilic N, Lauke H, Fiedler W, Pottek T, Kilic E, Freeman M, et al. Angiogenic switch and vascular stability in human leydig cell tumours. Angiogenesis. 1999;3:231–240
  17. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 2005;65:1294–1305
  18. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–563
  19. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002;20:4368–4380
  20. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003;9:653–660
  21. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000;6:389–395
  22. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol. 2002;160:1381–1392
  23. Weber CC, Cai H, Ehrbar M, Kubota H, Martiny-Baron G, Weber W, et al. Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization. J. Biol. Chem. 2005;280:22445–22453
  24. Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME, Li LY. Angiopoietin-1 and its receptor tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res. 1999;58:224–237
  25. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. 1999;79:213–223
  26. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000;6:460–463
  27. Schuch G, Oliveira-Ferrer L, Loges S, Laack E, Bokemeyer C, Hossfeld DK, et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia. 2005;
  28. Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. 2003;
  29. Moulton KS, Olsen BR, Sonn S, Fukai N, Zurakowski D, Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation. 2004;
  30. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285
  31. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003;4:31–39
  32. Hansen-Algenstaedt N, Joscheck C, Schaefer C, Lamszus K, Wolfram L, Biermann T, et al. Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. Eur. J. Cancer. 2005;41:1073–1085
  33. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 2000;14:2373–2376

PII: S0304-3835(05)00594-X

doi: 10.1016/j.canlet.2005.06.033

Cancer Letters
Volume 238, Issue 2 , Pages 180-187 , 18 July 2006

Article Tools

* Image Usage & Resolution